权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel Epigenetic regulators in cancer therapeutic resistance and as new targets

癌症治疗耐药性中的新型表观遗传调节因子及其新靶点

基本信息

批准号：
9339529
负责人：
Hongwu Chen
金额：
--
依托单位：
VA NORTHERN CALIFORNIA HEALTH CARE SYS
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-04-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9339529
关键词：
Ablation Androgen Antagonists Androgen Receptor Androgens Antiandrogen Therapy Apoptosis Automobile Driving Cancer Etiology Cause of Death Cell Survival Cells Cessation of life Clinical Data Clinical Trials Complex Developed Countries Developing Countries Diagnosis Disease Disease Progression Drug resistance Epigenetic Process Future Gene Expression Gene Targeting Genes Genomic approach Gleason Grade for Prostate Cancer Inflammation Inflammatory Malignant Neoplasms Malignant neoplasm of prostate Mediating Metastatic Prostate Cancer Modeling NF-kappa B Pathway interactions Patients Pharmaceutical Preparations Phosphotransferases Prognostic Marker Protein Methyltransferases Proteins Recurrent disease Resistance Resistance development Role Signal Pathway Signal Transduction Specimen Testing Time Treatment Efficacy Veterans autocrine base cancer therapy castration resistant prostate cancer chemotherapy docetaxel functional genomics histone methylation histone methyltransferase improved insight men novel overexpression personalized medicine programs prostate cancer cell public health relevance resistance mechanism small hairpin RNA taxane therapeutic target therapy resistant tumor tumor growth tumor progression tumor xenograft

项目摘要

DESCRIPTION (provided by applicant): Prostate cancer is still one of the leading causes of death in men of developed countries including the U. S., despite of the recent progress in its diagnosis and treatment. Although the advanced tumors initially respond to therapies such as androgen ablation, anti-androgen or the taxane-based chemotherapy, most of them develop resistance and the disease relapses. Therefore, there is an urgent need for better understanding of the resistance mechanisms and to identify markers and therapeutic targets for personalized treatment and improving survival. Current evidence supports the notion that multiple diverse pathways and mechanisms drive tumor resistance to different therapies including chemoresistance. Therefore, it will be highly significant if key resistance driving factors that interface the seemingly complex arrays of pathways can be identified. This proposal is based on our recent identification of an epigenetic regulator/histone methylase protein as a key factor of prostate cancer cell survival, proliferation and tumor growth. It functions as a novel co-activator of AR and NF-kB for induction of cell survival, pro-inflammatory gene and kinase signaling programs. Interestingly, it is induced by chemotherapeutic drugs and is overexpressed in prostate cancer tumors with high Gleason scores. Here, we wish to establish its function in driving chemoresistance and elucidate its functional mechanism as a key activator of multiple pathways involved in therapeutic resistance. We will also examine the epigenetic regulator for the potential value as a prognostic marker and a therapeutic target.

描述（由申请人提供）：前列腺癌仍然是包括美国在内的发达国家男性死亡的主要原因之一。美国，尽管最近在诊断和治疗方面取得了进展。虽然晚期肿瘤最初对雄激素消融、抗雄激素或紫杉烷类化疗等治疗有反应，但大多数肿瘤会产生耐药性，疾病会复发。因此，迫切需要更好地了解耐药机制，并确定个性化治疗和提高生存率的标志物和治疗靶点。目前的证据支持这样的观点：多种不同的途径和机制导致肿瘤对不同疗法（包括化学耐药性）产生耐药性。因此，如果能够识别出与看似复杂的途径阵列接口的关键抗性驱动因子，则将具有非常重要的意义。这个建议是基于我们最近鉴定的一种表观遗传调节因子/组蛋白甲基化酶蛋白作为前列腺癌细胞存活、增殖的关键因素和肿瘤生长。它作为AR和NF-kB的新型共激活剂用于诱导细胞存活、促炎基因和激酶信号传导程序。有趣的是，它是由化疗药物诱导的，并且在具有高Gleason评分的前列腺癌肿瘤中过表达。在这里，我们希望建立其在驱动化学抗性中的功能，并阐明其作为参与治疗抗性的多个途径的关键激活剂的功能机制。我们还将检查表观遗传调节因子作为预后标志物和治疗靶点的潜在价值。